Niagen Bioscience, Inc.
NAGE
$3.65
-$0.15-3.95%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 52.90% | -9.74% | 26.85% | -28.72% | -29.47% |
| Total Depreciation and Amortization | 46.23% | 2.05% | -0.51% | 0.51% | -77.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -15,888.24% | -99.12% | 9.95% | 3,223.21% | 98.77% |
| Change in Net Operating Assets | -39.52% | -22.14% | 30.20% | -260.54% | -47.54% |
| Cash from Operations | -275.85% | -81.61% | 195.36% | -84.14% | -8.16% |
| Capital Expenditure | 39.60% | -320.83% | 82.22% | -321.88% | 53.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 5,293.07% | -320.83% | 82.22% | -321.88% | 53.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 50.00% | -33.33% | 0.00% | -50.00% |
| Issuance of Common Stock | -51.32% | 50.00% | -95.95% | 20.49% | -17.86% |
| Repurchase of Common Stock | -837.85% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 14.55% | -- | 100.00% | 0.00% | 85.37% |
| Cash from Financing | -2,762.50% | -154.05% | -96.05% | 20.55% | -17.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 253.61% | -86.95% | -21.45% | -55.66% | -10.65% |